News

Fierce Biotech34m

FDA accelerates Stealth Bio’s rare disease application with a decision slated for next month

The FDA has accepted Stealth BioTherapeutics’ third new drug application for its ultra rare disease candidate, providing a ...
Fierce Biotech50m

Gilead’s Kite sails into in vivo CAR-T space with $350M Interius buyout

Gilead has become the latest pharma to strengthen its in-vivo cell therapy credentials this year, paying $350 million for CAR-T developer Interius BioTherapeutics. | Gilead has become the latest ...